Curative Biotechnology Inc

OTC Pink - Current Information:CUBTUnited States

Curative Biotechnology, Inc. is a development stage biomedical company focused on therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. It has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. It is focused on its degenerative eye disease platform. The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage age-related macular degeneration (AMD) disease. Its pipeline products include IMT504, CURB906, Metformin Reformulation, and COVID Vaccine with IMT504 Adjuvant. IMT504 is an immunotherapy for late-stage symptomatic rabies. CURB906 is a humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor.

Contact Information

Headquarters

1825 Nw Corporate Blvd., Suite 110BOCA RATON, FL, United States 33431

Phone

561-907-8990

Fax

---

Executives

Chairman of the Board, President

Paul Michaels

Chief Executive Officer, Chief Financial Officer, General Counsel

Richard Garr

Director

Michael Fish

Director, Chief Strategy Officer

Barry Ginsberg